- Home
- SUPV vs DRUG Comparison
SUPV vs DRUG Comparison
Compare SUPV & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | DRUG |
|---|---|---|
| Founded | 1887 | 2019 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 856.4M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SUPV | DRUG |
|---|---|---|
| Price | $8.37 | $77.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $13.00 | ★ $124.00 |
| AVG Volume (30 Days) | ★ 1.0M | 73.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.63 | N/A |
| Revenue Next Year | $43.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.54 | $23.18 |
| 52 Week High | $17.02 | $123.75 |
Technical Indicators
Market Signals| Indicator | SUPV | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 31.94 | 44.67 |
| Support Level | $4.71 | $77.80 |
| Resistance Level | $11.76 | $91.00 |
| Average True Range (ATR) | 0.62 | 4.56 |
| MACD | -0.19 | -0.75 |
| Stochastic Oscillator | 16.02 | 29.00 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.